Navigation Links
Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock
Date:7/22/2009

SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that it intends to offer, subject to market and other conditions, 9,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Orexigen expects to grant to the underwriter a 30-day option to purchase up to an additional 1,350,000 shares of common stock to cover overallotments, if any. All of the shares are being offered by Orexigen. Leerink Swann LLC is acting as sole book-running manager for the offering.

The securities described above are being offered by Orexigen pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. When available, copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Leerink Swann LLC , Attention: Syndicate Department, One Federal Street, 37th Fl., Boston, MA 02110 or by calling Leerink Swann LLC, toll free, at 1-800-808-7525, Ext. 4814.

About Orexigen(R) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave(R), has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product, Em
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
4. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
5. Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
6. Prime Therapeutics Receives TIPPS Certification
7. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
8. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
9. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
10. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
11. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... AZ (PRWEB) , ... August 30, 2015 , ... On ... College (EMCC), one of the 10 regionally accredited Maricopa Community Colleges , ... to network with college students pursuing employment information and opportunities. , The Expo has ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made ... the lives of patients, according to a newly published report. Surviving Mesothelioma has ... full article. , The authors of the new paper focus on several ...
(Date:8/29/2015)... AB (PRWEB) , ... August 29, 2015 , ... ... heart failure, angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are at ... such as angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia or ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... management, Decatur County Memorial Hospital recently transitioned management companies to partner with Wound ... Management for their outpatient wound center. , Transitioning wound care management providers ...
(Date:8/28/2015)... ... , ... With the goal of furthering music education programs in schools, the ... County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by Best ... the underfunded school districts of Mendon and its neighboring town of Quincy, IL. Best ...
Breaking Medicine News(10 mins):Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2
... How Eating Disorders Affect Loved Ones At ... The Remuda Cornerstone Bookstore on May 2, PHOENIX, ... the nation,s leading and largest inpatient,treatment center for women and ... with the authors of the new book "Distorted -,How a ...
... on human immune cell may be key to stopping infection ... at suppressing HIV target proteins lying on the virus itself, ... immune cells might work even better. , That,s because human ... the virus would have much less chance of mutating around ...
... More than 6,000 internists (doctors of internal medicine), ... meet in Washington, D.C., for Internal Medicine 2008, ... of Physicians (ACP), from May 15 - 17 ... Internal Medicine 2008 is the largest continuing medical ...
... 29 /PRNewswire-FirstCall/ - Traxxec,Ltd, the UK subsidiary of ... today announces that, in line with the licence ... at the Interpack conference,and trade show in Dusseldorf, ... will be present at this,meeting giving the Traxxec ...
... third of Downs syndrome children who wear bifocal lenses to ... for two years, according to new research from Cardiff University. ... Syndrome Research Unit has studied the reasons for poor focussing ... of the children in the study who adopted bifocals to ...
... April 29 Gunther von Hagens, BODY WORLDS, the,traveling ... this week. Though it will not be known if ... at BODY WORLDS in Los Angeles, or if,the honor ... in Milwaukee, or,Baltimore, or Manchester, England, the number is ...
Cached Medicine News:Health News:Authors Of New Critically Acclaimed Book 'Distorted' Share Their Journey From an Eating Disorder at a Book Signing Event in Wickenburg 2Health News:Researchers Tackle HIV From a New Angle 2Health News:Researchers Tackle HIV From a New Angle 3Health News:ACP hosts largest medical education meeting for general and subspecialty internists 2Health News:Columbia River Resources Inc subsidiary, Traxxec Ltd, reports coverage of its technology at Interpack 2008 (Pink Sheets OTC - CRVR.pk) 2Health News:Columbia River Resources Inc subsidiary, Traxxec Ltd, reports coverage of its technology at Interpack 2008 (Pink Sheets OTC - CRVR.pk) 3Health News:A life 'lens' ordinary 2Health News:Gunther Von Hagens' BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone 2Health News:Gunther Von Hagens' BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone 3
(Date:8/28/2015)... 28, 2015 Research and ... the "Investigation Report on China,s Tobramycin Market, 2010-2019" ... a traditional antibiotic whose eye drop and ointment are ... potential infection or inflammation caused by eye infection. Currently, ... are able to produce tobramycin, among which the Top ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Developed by ... Seroquel) is an important drug for the treatment ... in 2000, quetiapine was listed in the Catalogue ...
(Date:8/28/2015)... , Aug. 28, 2015 ... addition of the "Investigation Report on China,s Ranibizumab ... Developed by Novartis, ranibizumab was approved by CFDA to ... Currently, only Lucentis, a product of Novartis, is available ... the first self- developed drug for the treatment of ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... 7, 2011 Akorn, Inc. (NASDAQ: AKRX ... 2011, to discuss third quarter 2011 results followed by a ... day before the market opens. Subject: , Akorn, Inc. ... 2011, at 10:00 a.m. Eastern TimeDomestic Callers: , (888) ...
... PARSIPPANY, N.J., Oct. 7, 2011 Watson Pharmaceuticals, Inc. ... subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated ... Drug Administration (FDA) seeking approval to market Morphine Sulfate ... mg/2 mg, 60 mg/2.4 mg, 80 mg/3.2 mg, and ...
Cached Medicine Technology:Watson Confirms EMBEDA(R) Patent Challenge 2Watson Confirms EMBEDA(R) Patent Challenge 3
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
Uvex Patriot Frame...
Panoramic styling that contours closely to the face and brow. Saddle bridge fits average to fuller noses. Adjustable temple hinge adjusts up or down, longer or shorter. Soft cushion behind ear for co...
QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields....
Medicine Products: